Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Albugranin; Albumin fused G-CSF; CG-10639; Egranli; G-CSF/albumin human - Teva; Long-acting Granulocyte Colony Stimulating Factor (G-CSF) - Teva; Neugranin; Pegfilgrastim biosimilar - Teva

Latest Information Update: 13 Aug 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CoGenesys
  • Developer Teva Pharmaceutical Industries
  • Class Chemoprotectants; Granulocyte colony-stimulating factors
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Submission Withdrawal Neutropenia

Most Recent Events

  • 01 Jan 2015 Teva terminates phase II trial in Neutropenia (Chemotherapy-induced, In children, In adolscents) in USA, Bulgaria, Hungary, Romania, Russia, Ukraine, Poland, Georgia, Czech Republic and Slovakia (NCT01940601) prior to enrolment initiation
  • 04 Nov 2014 Regulatory submission withdrawn for Neutropenia (Chemotherapy-induced) in European Union (SC)
  • 26 Sep 2014 Preregistration for Neutropenia (Chemotherapy-induced) in European Union before September 2014 (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top